[1]王媛,李锁,冯素英.黏膜类天疱疮的研究进展[J].中国皮肤性病学杂志,2021,(09):1050-1053.[doi:10.13735/j.cjdv.1001-7089.202008036]
 WANG Yuan,LI Suo,FENG Suying.Update on Mucous Membrane Pemphigoid[J].The Chinese Journal of Dermatovenereology,2021,(09):1050-1053.[doi:10.13735/j.cjdv.1001-7089.202008036]
点击复制

黏膜类天疱疮的研究进展()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2021年09期
页码:
1050-1053
栏目:
综述
出版日期:
2021-09-01

文章信息/Info

Title:
Update on Mucous Membrane Pemphigoid
文章编号:
1001-7089(2021)09-1050-04
作者:
王媛李锁冯素英
中国医学科学院皮肤病医院(皮肤病研究所),北京协和医学院,江苏 南京210042
Author(s):
WANG YuanLI SuoFENG Suying
(Institute of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing 210042,China)
关键词:
黏膜类天疱疮 BP180 层粘连蛋白332 整合素α6β4
Keywords:
Mucous membrane pemphigoid BP180 Laminin 332 Integrin α6β4
分类号:
R 758.66
DOI:
10.13735/j.cjdv.1001-7089.202008036
文献标志码:
A
摘要:
黏膜类天疱疮是指一组慢性、异质性、自身免疫性表皮下水疱病,主要累及口腔、眼睛等黏膜,其特点是具有形成瘢痕的风险。患者体内存在抗基底膜带的自身抗体,分别是针对BP180、BP230、层粘连蛋白332、整合素α6β4,和Ⅶ型胶原,其中BP180的羧基端、层粘连蛋白332被认为是主要的自身抗原。诊断主要基于临床表现、组织病理及免疫学检查。治疗上应根据受累部位,疾病严重程度及进展速度,选择合适的治疗方案,为了尽量减少不可逆的损害,多学科合作诊疗是必要的。
Abstract:
Mucous membrane pemphigoid(MMP)is a heterogeneous group of chronic autoimmune subepithelial blistering diseases,predominantly affecting oral and ocular mucosae and is characterized by a risk for scarring.MMP is caused by autoantibodies against various autoantigens in the basement membrane zone,including BP180,BP230,laminin 332,integrin α6β4,and collagen Ⅶ.Of these,the C-terminus of BP180 and laminin 332 are thought to be major autoantigens for MMP.The diagnosis of MMP is based on the clinical presentation,histological and immunopathological findings.The appropriate approach to therapy is influenced by the following clinical factors:site(s)of involvement,severity of disease,rapidity of progression.Multidisciplinary management is often needed to minimize risk for adverse sequelae of this disease.

参考文献/References:

[1] Chan LS,Ahmed AR,Anhalt GJ,et al.The first international consensus on mucous membrane pemphigoid:definition,diagnostic criteria,pathogenic factors,medical treatment,and prognostic indicators[J].Arch Dermatol,2002,138(3):370-379.
[2] Schmidt E,Zillikens D.Pemphigoid diseases[J].Lancet,2013,381(9863):320-332.
[3] Kirzhner M,Jakobiec FA.Ocular cicatricial pemphigoid:a review of clinical features,immunopathology,differential diagnosis,and current management[J].Semin Ophthalmol,2011,26(4-5):270-277.
[4] Taylor J,Mcmillan R,Shephard M,et al.World Workshop on Oral Medicine Ⅵ:a systematic review of the treatment of mucous membrane pemphigoid[J].Oral Surg Oral Med Oral Pathol Oral Radiol,2015,120(2):161-171.
[5] Chiorean R,Danescu S,Virtic O,et al.Molecular diagnosis of anti-laminin 332(epiligrin)mucous membrane pem-phigoid[J].Orphanet J Rare Dis,2018,13(1):111.
[6] Imanishi A,Imanishi H,Hiroyasu S,et al.Anti-BP180-type mucous membrane pemphigoid immunoglobulin G shows heterogeneity of internalization of BP180/collagenⅩⅦ into keratinocyte cytoplasm[J].Med Mol Morphol,2016,49(2):89-97.
[7] Kamaguchi M,Iwata H,Nishie W,et al.The direct binding of collagen ⅩⅦ and collagen Ⅳ is disrupted by pemphigoid autoantibodies[J].Lab Invest,2019,99(1):48-57.
[8] Sezin T,Egozi E,Hillou W,et al.Anti-laminin-332 mucous membrane pemphigoid developing after a diphtheria tetanus vaccination[J].JAMA Dermatol,2013,149(7):858-862.
[9] Lazarova Z,Hsu R,Yee C,et al.Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model[J].J Invest Dermatol,2000,114(1):178-184.
[10] Heppe EN,Tofern S,Schulze FS,et al.Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological chara-cteristics of the human disease[J].J Invest Dermatol,2017,137(8):1709-1718.
[11] Shimanovich I,Nitz JM,Zillikens D.Multiple and repeated sampling increases the sensitivity of direct immunofluorescence testing for the diagnosis of mucous membrane pemphigoid[J].J Am Acad Dermatol,2017,77(4):700-705.
[12] Kamaguchi M,Iwata H,Ujiie I,et al.Direct immunofluorescence using non-lesional buccal mucosa in mucous membrane pemphigoid[J].Front Med(Lausanne),2018,5:20.
[13] Carey B,Setterfield J.Mucous membrane pemphigoid and oral blistering diseases[J].Clin Exp Dermatol,2019,44(7):732-739.
[14] Kamaguchi M,Iwata H.The diagnosis and blistering mechanisms of mucous membrane pemphigoid[J].Front Immunol,2019,10:34.
[15] Goletz S,Probst C,Komorowski L,et al.A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid[J].Br J Dermatol,2019,180(1):149-156.
[16] Chiorean R,Danescu S,Virtic O,et al.Molecular diagnosis of anti-laminin 332(epiligrin)mucous membrane pemphigoid[J].Orphanet J Rare Dis,2018,13(1):111.
[17] Maley A,Warren M,Haberman I,et al.Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid(MMP)[J].J Am Acad Dermatol,2016,74(5):835-840.
[18] Lamberts A,Euverman HI,Terra JB,et al.Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases[J].Front Immunol,2018,9:248.

相似文献/References:

[1]刘美娜,陈金波,陈柳青,等.大疱性类天疱疮中嗜酸性粒细胞募集机制研究进展[J].中国皮肤性病学杂志,2021,(04):454.[doi:10.13735/j.cjdv.1001-7089.202006097]
 LIU Meina,CHEN Jinbo,CHEN Liuqing,et al.Progress of the Research on the Mechanism of Recruitment of Eosinophils in Bullous Pemphigoid[J].The Chinese Journal of Dermatovenereology,2021,(09):454.[doi:10.13735/j.cjdv.1001-7089.202006097]

备注/Memo

备注/Memo:
[基金项目] 广西壮瑶医药与医养结合人才小高地(厅发〔2017〕44号)
[通信作者] 李彤,E-mail:2628521958@qq.com
更新日期/Last Update: 2021-09-01